Paul, J. (2014) Targeted survival improvements in clinical trials: are you an absolutist or relativist? Cancer, 121(3), pp. 335-338. (doi: 10.1002/cncr.29031) (PMID:25278175) (PMCID:PMC4328455)
|
Text
104154.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. 136kB |
Abstract
In this issue of Cancer, Castonguay et al highlight problems with reliably estimating the median OS in the control arm of clinical trials in ovarian cancer. This suggests that more careful reflection is generally required concerning how clinically relevant differences are determined and highlights further issues with the selection of overall survival as a primary endpoint. The article also raises questions regarding the prevalent standard statistical approach used to design and analyze studies with time to event outcomes.
| Item Type: | Articles (Editorial) |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Paul, Mr James |
| Authors: | Paul, J. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
| Journal Name: | Cancer |
| Publisher: | Wiley |
| ISSN: | 0008-543X |
| ISSN (Online): | 1097-0142 |
| Copyright Holders: | Copyright © 2014 The Author |
| First Published: | First published in Cancer 121(3):335-338 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information